2019 May 6. pii: S0896-8411(19)30043-5. doi: 10.1016/j.jaut.2019.04.021. [Epub ahead of print]

Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease.


Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disease characterized by neurological symptoms and signs of progressive weakness, paresthesias, and sensory dysfunction. Other symptoms include reduced or absent tendon reflexes, cranial nerve involvement, autonomic symptoms, ataxia, and neuropathic pain. Unlike other autoimmune diseases, CIDP generally affects older individuals and has a male predominance. The onset is generally insidious and can take up to 8 weeks with a relapsing-recovery pattern. Like all autoimmune diseases, the etiology is multifactorial, with both genetic and environmental factors contributing to it.

Case reports of CIDP have found associations with multiple pathogenic organisms including Hepatitis B and C viruses, Bartonella henselae, Mycoplasma pneumoniae, Human immunodeficiency virus, Cytomegalovirus and Epstein-Barr virus. Possible antigenic self-targets include myelin protein 0, myelin protein 2, peripheral myelin protein 22, Connexin 32, and myelin basic protein. Antibodies targeting the Ranvier node proteins such as contactin-1, contactin-associated protein 1, and neurofascin 155 have been described. CIDP is treated with rehabilitation and pharmacological modalities. Pharmacological treatments target autoimmune dysfunction and include corticosteroids, intravenous immunoglobulin, subcutaneous immunoglobulin, plasma exchange, immunosuppressive and immunomodulatory agents such as methotrexate, cyclophosphamide, rituximab, and mycophenolate mofetil. Although there are few observational studies and randomized clinical trials with limited evidence supporting the use of immunosuppressive drugs, they are widely used in clinical practice. A comprehensive review of CIDP is presented herein in light of the autoimmune tautology.



It’s a bit of a head-scratcher to me why they call this an autoimmune disease when it’s associated with multiple pathogenic organisms.  From everything I know – treat the infection and the symptoms improve:

That’s not to say the immune system doesn’t need to be addressed.

Lyme/MSIDS treatment includes both aspects as well as detoxification and addressing imbalances within the body which requires supplementation with whatever is lacking.

It is common knowledge that immunosuppressive drugs worsen Lyme/MSIDS patients, so they need to be used scrupulously and along with antimicrobials or the pathogens are in an environment where they are allowed to thrive, ultimately worsening the patient’s condition.

For more:  Excerpt:  

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. The disorder, which is sometimes called chronic relapsing polyneuropathy, is caused by damage to the myelin sheath (the fatty covering that wraps around and protects nerve fibers) of the peripheral nerves….It often presents with symptoms that include tingling or numbness (beginning in the toes and fingers), weakness of the arms and legs, loss of deep tendon reflexes (areflexia), fatigue, and abnormal sensations. CIDP is closely related to Guillain-Barre syndrome and it is considered the chronic counterpart of that acute disease.

The NIH link states the treatment is corticosteroids, but again, you’ve been warned that IF you have Lyme/MSIDS, that mono-therapy will make you worse.

Tingling, numbness, and stabbing pain are quite common in Lyme/MSIDS and many people with Epstein Barr (EBV) have misdiagnosed Lyme:  EBV – A Key Player in Chronic Illness.

Neuropathy is also common with Lyme/MSIDS: